T. Cardillo
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Chronic Lymphocytic Leukemia Research, Rheumatoid Arthritis Research and Therapies, Lipoproteins and Cardiovascular Health
Most-Cited Works
- → Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials(2020)368 cited
- → OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study(2015)26 cited
- → An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate‐to‐severe atopic dermatitis(2022)16 cited
- → THU0166 Safety Profile of Baricitinib in Patients with Active RA: An Integrated Analysis(2016)13 cited
- → Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients(2014)6 cited
- → 724 Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: The Triplet Trial(2012)5 cited
- → 041 Efficacy with continuous dosing, down-titration, or treatment withdrawal after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis(2021)3 cited
- → FRI0124 Temporary interruptions of study drug during the baricitinib phase 3 rheumatoid arthritis program(2017)1 cited
- → Efficacité et tolérance du baricitinib dans la dermatite atopique modérée à sévère: résultats de deux études de phase 3 en monothérapie sur 16 semaines, randomisées, en double-aveugle, contrôlées versus placebo (BREEZE-AD1 et BREEZE AD-2)(2019)
- → 084 Herpes virus infections amongst moderate to severe atopic dermatitis patients treated with baricitinib: an integrated analysis of phase 3 trials(2021)